← Ekachai Medical Care overview

Ekachai Medical Care vs SWS Hemodialysis Care Co. Ltd. A: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ekachai Medical Care Public Company Limited (EKH.BK)

Q3 2026
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

September 2026
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Latest
▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

  • Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.

    This is the key earnings result that shows EKH's core business is growing strongly.

  • New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.

    These new projects are the main growth drivers that will add revenue from Q3 2026 onward.

  • Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.

    This shows the positive trend continuing into Q3, confirming the growth story.

  • Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.

    Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

SWS Hemodialysis Care Co. Ltd. A (688410.CG)

Q3 2026
▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

  • H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.

    This is the main positive force behind the stock, showing strong underlying business momentum.

  • New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.

    New product approvals are a concrete growth driver that can lift future sales and investor confidence.

  • High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.

    The dividend is a new capital return event that supports the stock's appeal and shows financial health.

  • Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.

    This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

August 2026
▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

  • H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.

    This is the main positive force behind the stock, showing strong underlying business momentum.

  • New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.

    New product approvals are a concrete growth driver that can lift future sales and investor confidence.

  • High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.

    The dividend is a new capital return event that supports the stock's appeal and shows financial health.

  • Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.

    This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Latest
▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

  • H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.

    This is the main positive force behind the stock, showing strong underlying business momentum.

  • New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.

    New product approvals are a concrete growth driver that can lift future sales and investor confidence.

  • High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.

    The dividend is a new capital return event that supports the stock's appeal and shows financial health.

  • Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.

    This is the main counterweight to the positive news, explaining why the stock may face selling pressure.